Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Dyne Therapeutics, Inc. - Common Stock (NQ: DYN )

23.97 UNCHANGED
Streaming Delayed Price Updated: 1:00 PM EST, Dec 24, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Dyne Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 Next >
Dyne Therapeutics to Host Virtual Event Tomorrow, January 3 at 8:00 AM ET, to Present Initial Clinical Data from ACHIEVE and DELIVER Trials
From Dyne Therapeutics, Inc.
Via GlobeNewswire
3 of the Best Cheap Stocks Under $20 to Buy Now: November Edition
After dropping to 52-week lows, the markets have been rallying, sending traders and investors are looking for cheap stocks under $20. 
Via InvestorPlace
Dyne Therapeutics to Present at November Investor Conferences
From Dyne Therapeutics, Inc.
Via GlobeNewswire
Dyne Therapeutics Reports Third Quarter 2023 Financial Results and Provides Update on Significant Progress for ACHIEVE and DELIVER Trials and Upcoming Clinical Milestones
From Dyne Therapeutics, Inc.
Via GlobeNewswire
Why Shares of Dyne Therapeutics Fell This Week
Insiders sold more than 15,000 shares of company stock on Tuesday. 
Via The Motley Fool
Dyne Therapeutics to Present at October Investor Conferences
From Dyne Therapeutics, Inc.
Via GlobeNewswire
Dyne Therapeutics Receives FDA Orphan Drug Designation for DYNE-101 for the Treatment of Myotonic Dystrophy Type 1
From Dyne Therapeutics, Inc.
Via GlobeNewswire
Dyne Therapeutics to Present at Morgan Stanley 21st Annual Global Healthcare Conference
From Dyne Therapeutics, Inc.
Via GlobeNewswire
Dyne Therapeutics: Q1 Earnings Insights
Via Benzinga
What 4 Analyst Ratings Have To Say About Dyne Therapeutics
Via Benzinga
Dyne Therapeutics Reports Second Quarter 2023 Financial Results and Business Highlights
From Dyne Therapeutics, Inc.
Via GlobeNewswire
Dyne Therapeutics to Present at Jefferies Healthcare Conference
From Dyne Therapeutics, Inc.
Via GlobeNewswire
Dyne Therapeutics Receives European Medicines Agency (EMA) Orphan Drug Designation for DYNE-101
From Dyne Therapeutics, Inc.
Via GlobeNewswire
Dyne Therapeutics’ Preclinical Data Demonstrating FORCE™ Platform Delivery to CNS Featured in Oral Presentation at ASGCT Annual Meeting
From Dyne Therapeutics, Inc.
Via GlobeNewswire
Dyne Therapeutics Reports First Quarter 2023 Financial Results and Business Highlights
From Dyne Therapeutics, Inc.
Via GlobeNewswire
Dyne Therapeutics to Present at BofA Securities 2023 Healthcare Conference
From Dyne Therapeutics, Inc.
Via GlobeNewswire
Dyne Therapeutics to Present New Preclinical Data at ASGCT Annual Meeting Demonstrating FORCE™ Platform Delivery to CNS
From Dyne Therapeutics, Inc.
Via GlobeNewswire
Acuity Brands, C3.ai And Other Big Stocks Moving Lower On Tuesday
U.S. stocks traded lower, with the Dow Jones dropping more than 100 points on Tuesday. Here are some big stocks recording losses in today’s session. 
Via Benzinga
Dyne Therapeutics Receives FDA Orphan Drug and Rare Pediatric Designations for DYNE-251 for the Treatment of Duchenne Muscular Dystrophy
From Dyne Therapeutics, Inc.
Via GlobeNewswire
Dyne Therapeutics Announces Presentations on its DM1 and DMD Programs at the 2023 Muscular Dystrophy Association Clinical & Scientific Conference
From Dyne Therapeutics, Inc.
Via GlobeNewswire
Dyne Therapeutics to Present at Upcoming Investor Conferences
From Dyne Therapeutics, Inc.
Via GlobeNewswire
Dyne Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Business Highlights
From Dyne Therapeutics, Inc.
Via GlobeNewswire
Analyst Says This Small Cap Biotech Firm Has 'Very Valuable Therapeutic,' Upgrades Stock
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For February 27, 2023
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For February 15, 2023
Via Benzinga
12 Health Care Stocks Moving In Tuesday's After-Market Session
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For January 26, 2023
Via Benzinga
Dyne Therapeutics to Present at 41st Annual J.P. Morgan Healthcare Conference
From Dyne Therapeutics, Inc.
Via GlobeNewswire
$10 Million Bet On Dyne Therapeutics? Check Out These 4 Stocks Insiders Are Buying
Although US stocks closed lower on Wednesday following Fed’s rate decision, there were a few notable insider trades. 
Via Benzinga
Why Netcapital Shares Are Trading Lower By Over 33%? Here Are 50 Stocks Moving In Wednesday's Mid-Day Session
Gainers Crown ElectroKinetics Corp. (NASDAQ: CRKN) shares rose 153% to $0.3325 after gaining 14% on Tuesday. Crown ElectroKinetics, last month, posted a Q3 loss of $0.18 per share. 
Via Benzinga
< Previous 1 2 3 4 5 6 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.